MaltSci 麦伴科研

Appearance

Popular Reports / Neuroscience

This report is written by MaltSci based on the latest literature and research findings

What are the treatments for cognitive impairment? ​

Abstract ​

Cognitive impairment is a pressing public health concern, particularly among aging populations, impacting millions worldwide. This review examines the spectrum of treatments available for cognitive impairment, which includes both pharmacological and non-pharmacological strategies. Pharmacological treatments such as cholinesterase inhibitors and NMDA receptor antagonists have shown efficacy in managing cognitive decline associated with conditions like Alzheimer's disease and schizophrenia, though their effectiveness can vary among individuals. Non-pharmacological interventions, including cognitive training, physical exercise, and nutritional strategies, have gained traction, with evidence supporting their role in enhancing cognitive function and improving quality of life. Additionally, emerging therapies such as neurostimulation techniques, stem cell therapy, and gene therapy are being investigated for their potential to address the underlying causes of cognitive decline. A multidisciplinary approach, integrating the expertise of healthcare providers and the involvement of family support, is crucial for optimizing treatment outcomes. This review underscores the importance of personalized treatment plans that consider individual patient needs and preferences, advocating for a holistic view of cognitive health that combines various therapeutic modalities. Future research should focus on refining these strategies and exploring innovative interventions to improve the management of cognitive impairment and enhance the quality of life for those affected.

Outline ​

This report will discuss the following questions.

  • 1 Introduction
  • 2 Understanding Cognitive Impairment
    • 2.1 Definition and Types of Cognitive Impairment
    • 2.2 Causes and Risk Factors
  • 3 Pharmacological Treatments
    • 3.1 Cholinesterase Inhibitors
    • 3.2 NMDA Receptor Antagonists
    • 3.3 Other Pharmacological Agents
  • 4 Non-Pharmacological Interventions
    • 4.1 Cognitive Training and Rehabilitation
    • 4.2 Physical Exercise
    • 4.3 Nutritional Interventions
  • 5 Emerging Therapies and Future Directions
    • 5.1 Neurostimulation Techniques
    • 5.2 Stem Cell Therapy
    • 5.3 Gene Therapy
  • 6 Multidisciplinary Approaches to Treatment
    • 6.1 Role of Healthcare Providers
    • 6.2 Importance of Family Support
  • 7 Summary

1 Introduction ​

Cognitive impairment represents a critical public health issue, affecting millions globally, particularly among the elderly. This condition encompasses a spectrum of disorders that compromise cognitive functions such as memory, reasoning, and social abilities, ultimately diminishing individuals' quality of life and daily functioning. The growing prevalence of cognitive impairment is largely attributed to demographic shifts, particularly aging populations, as well as the increasing incidence of neurodegenerative diseases and lifestyle-related factors. Given these trends, there is an urgent need to explore and implement effective treatment strategies for cognitive impairment, which has significant implications for healthcare systems and society at large [1].

The significance of addressing cognitive impairment cannot be overstated. Cognitive decline is not only associated with neurodegenerative conditions like Alzheimer’s disease and Parkinson’s disease but also with other disorders such as schizophrenia and multiple sclerosis [2][3]. Furthermore, cognitive impairment can lead to increased dependency, reduced quality of life, and heightened healthcare costs, emphasizing the necessity for effective interventions [4]. Research into treatment modalities is vital to improving outcomes for affected individuals, facilitating their ability to engage in everyday activities and maintain independence [5].

Current research on cognitive impairment treatment has made significant strides, revealing a variety of pharmacological and non-pharmacological interventions. Pharmacological treatments include cholinesterase inhibitors and NMDA receptor antagonists, which have shown promise in managing symptoms of cognitive decline associated with Alzheimer’s disease and other dementias [6][7]. However, the efficacy of these medications can vary, and they often come with adverse effects, highlighting the need for complementary non-pharmacological strategies [5][8]. Non-pharmacological interventions such as cognitive training, physical exercise, and mindfulness-based therapies are gaining traction, with evidence suggesting they can improve cognitive function and overall well-being [5][9].

The present review aims to provide a comprehensive overview of the current treatments available for cognitive impairment, structured as follows: Section 2 will define cognitive impairment and discuss its various types, causes, and risk factors. Section 3 will delve into pharmacological treatments, exploring the mechanisms and effectiveness of cholinesterase inhibitors, NMDA receptor antagonists, and other agents. In Section 4, we will examine non-pharmacological interventions, highlighting the role of cognitive training, physical exercise, and nutritional strategies in enhancing cognitive health. Section 5 will address emerging therapies, including neurostimulation techniques and innovative approaches like stem cell and gene therapy. Section 6 will focus on the importance of multidisciplinary care in managing cognitive impairment, emphasizing the collaboration among healthcare providers and the involvement of family support. Finally, Section 7 will summarize the key findings and suggest future directions for research and practice.

Through synthesizing the latest research findings, this review will illuminate the efficacy and limitations of existing treatment options for cognitive impairment. It will also underscore the necessity for personalized approaches tailored to the unique needs of individuals, advocating for a holistic view of cognitive health that integrates both pharmacological and non-pharmacological strategies. The insights derived from this review will serve as a valuable resource for clinicians, researchers, and policymakers dedicated to improving the management of cognitive impairment and enhancing the quality of life for those affected.

2 Understanding Cognitive Impairment ​

2.1 Definition and Types of Cognitive Impairment ​

Cognitive impairment refers to a range of cognitive deficits that can affect various domains such as memory, attention, executive function, and social cognition. This condition is commonly observed in various neurodegenerative disorders, including multiple sclerosis (MS), schizophrenia, Parkinson's disease, and dementia. The treatment of cognitive impairment encompasses both pharmacological and non-pharmacological approaches, which can be tailored based on the underlying condition and individual patient needs.

In the context of multiple sclerosis, cognitive impairment is prevalent, with up to 65% of patients experiencing deficits in areas such as episodic memory and information processing speed. The treatment strategies include disease-modifying drugs (DMDs) that may improve cognitive performance, alongside symptomatic treatments like cognitive rehabilitation and physical activity interventions. Recent studies have indicated that cognitive rehabilitation can significantly enhance cognitive function in MS patients, though challenges remain in effectively managing these cognitive issues [3][10].

For schizophrenia, cognitive impairment is a core symptom that complicates treatment outcomes. Current recommendations from the European Psychiatric Association emphasize the use of second-generation antipsychotics due to their favorable cognitive profiles. Additionally, psychosocial interventions, such as cognitive remediation and physical exercise, are advised to address cognitive deficits [2].

In cases of mild cognitive impairment and dementia, non-pharmacological interventions have gained attention as there are currently no disease-modifying pharmacological treatments. Mindfulness and cognitive training have shown potential benefits in improving cognitive function and mood. Studies suggest these interventions can enhance aspects of cognition such as attention and memory, although further research is necessary to clarify their effectiveness [8].

For Parkinson's disease, cognitive impairment poses significant challenges. While pharmacological options remain limited, multimodal interventions combining cognitive training, exercise, and non-invasive brain stimulation are being explored. Such integrative approaches have shown promise in improving cognitive functions [7][11].

In summary, the treatment of cognitive impairment is multifaceted and may include pharmacological therapies, cognitive rehabilitation, physical exercise, and mindfulness techniques. The selection of appropriate interventions should be individualized, taking into account the specific cognitive deficits, underlying conditions, and patient preferences. Continued research is essential to refine these treatment strategies and improve outcomes for individuals experiencing cognitive impairment across various disorders.

2.2 Causes and Risk Factors ​

Cognitive impairment is a significant concern across various neurological and psychiatric conditions, and numerous treatment strategies have been explored to address this issue. The treatments can be broadly categorized into pharmacological and non-pharmacological interventions.

Pharmacological treatments vary depending on the underlying condition causing cognitive impairment. For instance, in schizophrenia, second-generation antipsychotics are recommended for their favorable cognitive profiles, while anticholinergic and benzodiazepine burdens should be minimized due to their negative impact on cognitive functioning [2]. In Alzheimer's disease and Lewy body dementia, cholinesterase inhibitors have shown promise in improving cognitive symptoms [12], and ongoing trials are exploring various other pharmacological agents [12].

For multiple sclerosis (MS), cognitive impairment is prevalent, with some disease-modifying therapies showing potential benefits in cognitive performance, although no specific pharmacological treatments have been established for cognitive dysfunction [13]. Cognitive rehabilitation and exercise training are highlighted as effective non-pharmacological strategies to mitigate cognitive problems in MS [10].

Non-pharmacological interventions encompass a wide range of approaches. Cognitive remediation has been shown to improve cognitive function in schizophrenia, focusing on enhancing attention, memory, and executive function [14]. Mindfulness and cognitive training interventions have been studied in mild cognitive impairment, demonstrating potential benefits in cognition and mood [8]. Similarly, physical-cognitive rehabilitation has emerged as a particularly effective strategy for enhancing cognition in dementia and unspecified cognitive impairment [4].

Additionally, acupoint stimulation has been investigated for its neuroprotective effects and ability to improve cognitive function by promoting neural regeneration and regulating synaptic plasticity [15]. The integration of exercise with cognitive training has also shown promising results in improving cognitive outcomes in Parkinson's disease [11].

In summary, the treatment landscape for cognitive impairment is diverse, incorporating both pharmacological agents tailored to specific conditions and a variety of non-pharmacological interventions aimed at enhancing cognitive function and quality of life. As research progresses, further elucidation of these treatment modalities will be essential in optimizing care for individuals experiencing cognitive deficits.

3 Pharmacological Treatments ​

3.1 Cholinesterase Inhibitors ​

Cholinesterase inhibitors (ChEIs) represent a significant pharmacological approach for treating cognitive impairment associated with various forms of dementia and other neurological conditions. These agents function by inhibiting the enzyme acetylcholinesterase, which breaks down the neurotransmitter acetylcholine, thereby enhancing cholinergic transmission. This mechanism is particularly relevant in conditions characterized by cholinergic deficits, such as Alzheimer's disease and Parkinson's disease dementia.

Numerous studies have evaluated the efficacy of ChEIs in different patient populations. For instance, in the context of Alzheimer's disease, cholinesterase inhibitors like donepezil, rivastigmine, and galantamine have been shown to provide symptomatic relief, particularly in improving cognitive functions and potentially delaying the progression of cognitive decline. A systematic review indicated that donepezil 5 mg and 10 mg and galantamine 16 to 24 mg likely improve cognition, although the clinical significance of these improvements may be modest [16]. Furthermore, a cohort study demonstrated that ChEIs could reduce global cognitive decline over one to two years, particularly affecting executive functioning and visuospatial skills [17].

In the context of vascular cognitive impairment (VCI), which encompasses a range of cognitive deficits due to cerebrovascular disease, evidence suggests that ChEIs may also have beneficial effects. Randomized controlled trials have shown that these agents can improve cognitive function in patients with vascular dementia [18].

ChEIs have also been investigated for their effects in treating cognitive impairment associated with Parkinson's disease. The strongest evidence supports their use in managing cognitive symptoms in this population, indicating that these drugs can improve cognitive function and possibly influence behavioral symptoms [19]. Moreover, they have been considered for use in rarer dementias, such as those linked to neurological conditions, with varying degrees of efficacy reported [20].

In addition to their primary effects on cognition, ChEIs may also impact behavioral symptoms and the overall quality of life for patients with dementia [21]. The side effects of ChEIs, which may include gastrointestinal issues such as nausea and diarrhea, are important considerations in their clinical use, but they remain a cornerstone of pharmacological treatment for cognitive impairment [22].

Overall, cholinesterase inhibitors are a well-established class of medications that provide therapeutic options for cognitive impairment across a spectrum of neurological disorders, demonstrating varying degrees of efficacy and safety profiles depending on the specific condition being treated.

3.2 NMDA Receptor Antagonists ​

Cognitive impairment is a significant challenge in various psychiatric and neurological disorders, including bipolar disorder and schizophrenia. Among the pharmacological treatments, N-methyl-D-aspartate (NMDA) receptor antagonists have emerged as a potential strategy for addressing cognitive deficits associated with these conditions.

In the context of bipolar disorder, recent reviews indicate that NMDA receptor-modulating agents may improve cognitive function. Memantine, for instance, has been identified as an effective add-on therapy, demonstrating improvements in cognitive issues such as memory enhancement following traumatic brain injury (TBI) and in treatment-resistant bipolar disorder patients. Additionally, ketamine infusions have shown promise in improving processing speed and verbal learning in individuals with bipolar disorder (Badrfam & Zandifar, 2025) [23].

Similarly, in schizophrenia, cognitive impairment is a core feature that adversely affects patients' functional outcomes. NMDA receptors are critical for synaptic transmission and plasticity, making them a target for therapeutic intervention. Emerging pharmacological strategies targeting NMDA receptors have been highlighted as potential treatments for cognitive deficits in schizophrenia. Research indicates that NMDA receptor antagonists can model cognitive dysfunction and negative symptoms of schizophrenia, providing a basis for developing novel therapies (Zhang et al., 2024) [24]. Moreover, the use of animal models has demonstrated that NMDA receptor antagonism can produce cognitive deficits that parallel those seen in schizophrenia, thereby facilitating the evaluation of new pharmacological agents aimed at ameliorating these cognitive impairments (Neill et al., 2010) [25].

The therapeutic potential of NMDA receptor antagonists extends to addressing cognitive deficits associated with neurodegenerative conditions. Memantine, a clinically well-tolerated NMDA receptor antagonist, has shown efficacy in treating Alzheimer's disease and other neurodegenerative disorders, indicating its potential for cognitive enhancement in various contexts (Parsons et al., 1999) [26].

Despite the promise shown by NMDA receptor antagonists, there are challenges associated with their use, particularly concerning side effects. High-affinity NMDA antagonists, such as MK-801 and phencyclidine (PCP), are known to induce psychotomimetic effects, limiting their clinical applicability. In contrast, low-affinity antagonists like memantine are better tolerated and are currently used in clinical settings (Kornhuber & Weller, 1997) [27].

In conclusion, NMDA receptor antagonists represent a significant area of interest in the pharmacological treatment of cognitive impairments associated with various psychiatric and neurological disorders. Continued research into their mechanisms, efficacy, and safety profiles is essential to fully realize their therapeutic potential in enhancing cognitive function and addressing the unmet needs in the treatment of cognitive deficits.

3.3 Other Pharmacological Agents ​

Cognitive impairment, a condition frequently observed in various psychiatric and neurological disorders, has prompted extensive research into pharmacological treatments. Among these, several agents beyond traditional medications have been investigated for their potential to enhance cognitive function.

One significant category of pharmacological agents includes cholinesterase inhibitors, such as donepezil, which have been primarily used in Alzheimer's disease. While donepezil has shown some promise in improving cognitive deficits, its efficacy in schizophrenia has been less favorable. Clinical trials have indicated disappointing results when donepezil is used as an adjunct to second-generation antipsychotics for cognitive enhancement in schizophrenia, suggesting that its role may not be as beneficial as hoped in this population (Thakurathi et al. 2013) [28].

In addition to cholinesterase inhibitors, the selective phosphodiesterase type 4 (PDE4) inhibitor, roflumilast, has emerged as a potential cognitive enhancer. Originally approved for the treatment of chronic obstructive pulmonary disease, roflumilast has demonstrated pro-neuroplasticity and anti-inflammatory effects in preclinical studies. It has shown cognition-enhancing effects in healthy adults and those with mild cognitive impairment (MCI) and schizophrenia, suggesting a favorable therapeutic window for cognitive enhancement at lower doses (Prickaerts et al. 2024) [29].

Moreover, various other pharmacological agents have been explored for their cognitive-enhancing properties. For instance, the use of CNS stimulants like methylphenidate and modafinil has been proposed for cognitive dysfunction resulting from cancer therapies. These agents have shown variable efficacy in managing cognitive symptoms, emphasizing the need for further research to establish their clinical value in this context (Karschnia et al. 2019) [30].

The literature also highlights the potential role of N-methyl-D-aspartate receptor (NMDAR) enhancers, which have been reported to improve cognitive function in patients with chronic schizophrenia. However, the results remain mixed, necessitating larger clinical trials to ascertain their effectiveness (Hsu et al. 2018) [31].

In summary, while several pharmacological agents are being investigated for cognitive enhancement, the results have been inconsistent across different conditions. The use of cholinesterase inhibitors like donepezil has shown limited efficacy in schizophrenia, while newer agents like roflumilast and various CNS stimulants may offer promising avenues for further research. Continued exploration of these and other pharmacological treatments is essential to develop effective strategies for managing cognitive impairment across diverse patient populations.

4 Non-Pharmacological Interventions ​

4.1 Cognitive Training and Rehabilitation ​

Cognitive impairment, particularly in conditions such as mild cognitive impairment (MCI) and dementia, presents significant challenges, and the exploration of non-pharmacological interventions has gained considerable attention in recent years. Among these interventions, cognitive training and rehabilitation have emerged as prominent strategies aimed at enhancing cognitive function and improving the quality of life for affected individuals.

Cognitive training encompasses a range of structured activities designed to improve specific cognitive skills such as memory, attention, and executive functions. This approach often includes exercises tailored to stimulate cognitive processes, thereby potentially delaying the progression of cognitive decline. For instance, systematic reviews have highlighted the effectiveness of cognitive training in individuals with MCI, noting that while the results can be modest, there is evidence supporting its ability to enhance cognitive performance [32][33].

Cognitive rehabilitation, on the other hand, is a more holistic approach that not only targets cognitive deficits but also addresses the functional impacts of these deficits on daily living. This intervention is often tailored to the individual’s specific needs and can involve a combination of cognitive exercises, compensatory strategies, and support for daily activities. Evidence suggests that cognitive rehabilitation can yield positive outcomes, particularly in improving the functional abilities of individuals with Alzheimer's disease and other forms of dementia [34][35].

Recent systematic reviews have compared various non-pharmacological treatments, concluding that cognitive training and rehabilitation can offer significant benefits. For example, a network meta-analysis found that physical-cognitive rehabilitation was particularly effective in enhancing global cognition in patients with unspecified cognitive impairment and dementia [4]. Furthermore, cognitive training combined with other modalities, such as physical exercise, has shown promise in improving cognitive functions in populations with Parkinson's disease [11].

Moreover, cognitive interventions are not only beneficial for cognitive functions but also for mood and overall quality of life. Studies indicate that mindfulness and cognitive training can alleviate symptoms of depression and anxiety in individuals with MCI, contributing to a better overall well-being [8].

Despite the encouraging findings, it is important to acknowledge the variability in the effectiveness of these interventions due to differences in study designs, participant characteristics, and intervention specifics. Many studies have called for more rigorous, large-scale randomized controlled trials to better establish the efficacy and optimize the delivery of cognitive training and rehabilitation strategies [36][37].

In conclusion, cognitive training and rehabilitation represent valuable non-pharmacological interventions for managing cognitive impairment. They hold the potential to improve cognitive abilities and enhance the quality of life for individuals affected by MCI and dementia, though ongoing research is essential to refine these approaches and confirm their long-term benefits.

4.2 Physical Exercise ​

Cognitive impairment, particularly in older adults, has garnered significant attention due to the absence of effective pharmacological treatments. Consequently, non-pharmacological interventions, particularly physical exercise, have emerged as a prominent area of research and application. Various studies have highlighted the efficacy of physical exercise in improving cognitive function among individuals with mild cognitive impairment (MCI) and other neurocognitive disorders.

A systematic review and network meta-analysis by Venegas-Sanabria et al. (2024) revealed that physical-cognitive rehabilitation is the most effective non-pharmacological intervention for enhancing global cognition in patients with unspecified cognitive impairment and dementia. Additionally, occupational therapy focused on dual-task interventions was identified as particularly beneficial for individuals with mild cognitive impairment [4].

Wang et al. (2023) conducted a comprehensive analysis that included 39 randomized controlled trials involving 3,157 participants. Their findings indicated that physical exercise (PE) was the most effective intervention for slowing cognitive decline, with a standardized mean difference (SMD) of 1.34 (95% CI: 0.80, 1.89) [36]. This reinforces the notion that physical activity serves as a crucial component in managing cognitive impairment.

Moreover, a meta-analysis by Groot et al. (2016) synthesized data from 18 randomized controlled trials, indicating a positive overall effect of physical activity interventions on cognitive function in dementia patients, with an SMD of 0.42 (95% CI: 0.23; 0.62) [38]. This analysis emphasized that both aerobic and combined exercise interventions yielded significant cognitive benefits, independent of the specific dementia diagnosis.

Farì et al. (2021) further elaborated on the neurobiological effects of physical exercise, noting its ability to promote neuroplasticity and neuroprotection through various physiological mechanisms, including cytokine and hormonal modulation [39]. These findings underscore the potential of exercise not only as a therapeutic intervention but also as a preventive measure against cognitive decline.

In addition to aerobic exercises, other modalities such as strength training, tai chi, and mind-body exercises have been included in the repertoire of non-pharmacological interventions. These diverse approaches highlight the multifaceted nature of physical activity and its adaptability to individual patient needs.

Despite the promising results, it is important to acknowledge the variability in study designs and outcomes. For instance, Rodakowski et al. (2015) noted that while cognitive training and physical exercise may lead to small improvements in cognitive abilities, the methodological limitations of existing studies necessitate cautious interpretation of the results [33].

In summary, physical exercise represents a vital non-pharmacological intervention for cognitive impairment, demonstrating substantial evidence of efficacy across various studies. Its role in enhancing cognitive function, particularly through modalities that promote physical-cognitive rehabilitation, suggests a dual approach that integrates both physical and cognitive elements into treatment strategies. Future research should continue to explore optimal exercise regimens and their long-term effects on cognitive health.

4.3 Nutritional Interventions ​

Cognitive impairment is a significant public health concern, especially among aging populations. Non-pharmacological interventions, particularly nutritional interventions, have gained attention for their potential to mitigate cognitive decline. A systematic review and network meta-analysis by Peng et al. (2024) highlighted that nutritional support is one of the most effective non-pharmacological interventions for improving frailty and cognitive function in patients with cognitive frailty. This analysis included 19 randomized controlled trials involving 1738 patients and emphasized the role of nutritional interventions in enhancing cognitive outcomes[40].

Nutritional interventions encompass a variety of dietary strategies aimed at improving cognitive health. A comprehensive narrative review by Fekete et al. (2023) examined the effects of various nutritional supplements, including vitamins, minerals, and antioxidants, on cognitive function in aging individuals. The review found that while some supplements exhibited promising results in enhancing cognitive performance, others demonstrated limited or context-dependent effectiveness. Factors such as dosage, bioavailability, and individual differences in response to supplementation were also identified as critical determinants of efficacy[41].

Moreover, Klímová and Vališ (2018) explored the impact of nutritional interventions on delaying cognitive decline in healthy older individuals. Their findings indicated that dietary strategies, particularly the Mediterranean diet, could positively influence cognitive function. They noted that interventions combining multiple nutrients tend to be more effective than single-nutrient approaches[42].

In addition to specific dietary patterns, the efficacy of various nutrients has been examined in the context of cognitive impairment. Vlachos and Scarmeas (2019) reviewed randomized clinical trials focusing on dietary interventions in mild cognitive impairment and dementia, highlighting the potential benefits of nutrients such as folate, vitamin E, and omega-3 fatty acids. However, they emphasized the need for larger, well-designed trials to confirm these preliminary findings and establish clearer guidelines for clinical practice[43].

Furthermore, Gutierrez et al. (2021) conducted a systematic review of randomized controlled trials assessing the effects of dietary interventions on cognitive function. Their analysis suggested that dietary patterns, particularly the Mediterranean diet, alongside specific food and dietary supplements, could improve cognitive domains or measures of brain integrity. The review also indicated that while some dietary supplements, especially polyphenols, showed strong evidence of cognitive benefits, others had mixed results, underscoring the need for further research to solidify these findings[44].

In summary, non-pharmacological interventions, particularly nutritional strategies, present a promising avenue for addressing cognitive impairment. These interventions include dietary patterns such as the Mediterranean diet, specific nutrient supplementation, and the combination of multiple dietary approaches. Continued research is essential to better understand the mechanisms and efficacy of these interventions, ultimately guiding healthcare professionals in their application for cognitive health improvement.

5 Emerging Therapies and Future Directions ​

5.1 Neurostimulation Techniques ​

Cognitive impairment is a significant concern in various neurodegenerative and neuropsychiatric disorders, and while traditional pharmacological treatments have limitations, emerging therapies focusing on neurostimulation techniques are gaining attention for their potential benefits.

Transcranial magnetic stimulation (TMS) is one of the prominent non-invasive neuromodulation techniques employed to address cognitive impairment. It works by inducing electrical currents in targeted brain regions, which can alter neural activity and enhance cognitive functions. Recent bibliometric analyses indicate a growing body of research on TMS, highlighting its application in cognitive rehabilitation across different conditions, including Alzheimer’s disease and schizophrenia. The technique has shown promise in improving cognitive functions such as attention and memory, although results can vary based on individual response and methodological differences in studies [45][46].

Another neurostimulation method is transcranial direct current stimulation (tDCS), which involves applying a low electrical current to the scalp to modulate neuronal excitability. This technique has been explored in conjunction with cognitive training to enhance executive functioning and memory in various populations, including those with mild cognitive impairment and Parkinson's disease. Studies suggest that tDCS, when paired with cognitive interventions, may lead to significant improvements in cognitive performance [11].

Additionally, the integration of non-invasive brain stimulation techniques with cognitive rehabilitation strategies is being researched. For instance, multimodal approaches that combine exercise, cognitive training, and neuromodulation techniques are showing potential for enhancing cognitive outcomes in conditions such as Parkinson's disease [11].

Acupoint stimulation, a traditional approach that has gained traction in recent years, also shows promise in treating cognitive impairment. Research indicates that acupoint stimulation can improve memory and cognitive function by protecting neurons, reducing inflammation, and promoting synaptic plasticity. These mechanisms may be beneficial in managing symptoms associated with cognitive disorders [15].

The future of treating cognitive impairment likely involves a combination of pharmacological and non-pharmacological strategies, including these neurostimulation techniques. Continued research is essential to refine these interventions, establish optimal protocols, and understand their long-term effects on cognitive health. The integration of personalized approaches, based on individual neurophysiological profiles, may enhance the efficacy of these treatments [47].

In conclusion, emerging neurostimulation techniques represent a promising frontier in the treatment of cognitive impairment, with the potential to significantly improve cognitive outcomes and quality of life for affected individuals. Further studies are necessary to elucidate the most effective combinations and applications of these interventions.

5.2 Stem Cell Therapy ​

Cognitive impairment, particularly in the context of aging and certain medical therapies, has garnered increasing attention in recent years. Among the emerging treatments for cognitive impairment, stem cell therapy has shown promise as a potential intervention, particularly for conditions such as cognitive frailty and cancer-related cognitive impairment (CRCI).

Cognitive frailty, characterized by a combination of physical frailty and cognitive decline, is increasingly recognized as a significant issue affecting the elderly. It is associated with various pathophysiological mechanisms, including chronic inflammatory responses, immunological hypofunction, and oxidative stress. Research indicates that mesenchymal stem cell (MSC) transplantation may provide a therapeutic avenue for addressing cognitive frailty. MSCs possess regenerative properties that can target inflammation and oxidative damage, potentially reversing or mitigating cognitive decline associated with aging and frailty [48].

In the context of hematopoietic stem cell transplantation (HCT) and chimeric antigen receptor (CAR) T-cell therapy, cognitive impairment is a common complication that can manifest as acute conditions such as transplant-associated altered mentation and long-term issues like CRCI. The consensus recommendations from experts emphasize the importance of cognitive assessment using validated tools before and after therapy, highlighting the need for interventions that could include stem cell therapy as a part of a comprehensive management plan [49].

The application of stem cell therapy for cognitive impairment is still in its early stages, but it holds potential due to the ability of stem cells to promote neuroprotection and enhance regenerative processes in the brain. Ongoing research aims to clarify the mechanisms through which stem cells exert their effects on cognitive function, and to develop standardized protocols for their application in clinical settings [48][49].

Furthermore, the use of stem cells in the treatment of neurological disorders has been extensively studied, with findings suggesting that various types of stem cells, including induced pluripotent stem cells and adult neural stem cells, can potentially be utilized to treat cognitive deficits. These therapies may involve direct neural regeneration or the modulation of inflammatory responses that contribute to cognitive decline [50].

In summary, while traditional therapeutic approaches for cognitive impairment have limitations, emerging therapies, particularly stem cell-based interventions, offer a promising future direction. These therapies not only aim to restore cognitive function but also address underlying pathophysiological mechanisms, thereby improving the overall quality of life for affected individuals. Continued research and clinical trials will be essential to establish the efficacy and safety of these innovative treatments.

5.3 Gene Therapy ​

Cognitive impairment, including conditions such as Alzheimer's disease (AD) and mild cognitive impairment, currently lacks universally effective treatments. Existing therapies are often limited by adverse effects associated with polypharmacy and a lack of targeted options. Recent advancements in gene therapy present a promising avenue for addressing the underlying genetic and molecular mechanisms contributing to cognitive decline.

Gene therapy aims to correct genetic abnormalities that contribute to neurological disorders, potentially offering a permanent solution through the deletion, silencing, or editing of faulty genes, as well as the insertion of healthier genes. In the context of cognitive impairment, a study identified several key genes associated with cognitive decline through integrative genomic analyses. Specifically, the Mendelian randomization (MR) analysis highlighted three significant gene-eQTL pairs: HNMT (involved in histamine metabolism), TNFSF8 (related to inflammatory signaling), and S1PR5 (linked to sphingolipid signaling). These genes have been prioritized as potential therapeutic targets, with 39, 24, and 30 predicted drugs associated with each, respectively, including arsenic trioxide, aspirin, and various immunomodulators[51].

The application of gene therapy in cognitive impairment is supported by the growing body of research focused on identifying novel therapeutic targets and improving delivery methods. Advances in vector design, including viral and non-viral delivery systems, are critical for ensuring that therapeutic genes reach their intended sites within the brain. Furthermore, innovative techniques such as CRISPR-based therapies and nanotechnology are being explored to enhance the precision and effectiveness of gene delivery[52].

In addition to gene therapy, other emerging treatments for cognitive impairment include immunomodulatory approaches, which aim to address inflammatory processes that may contribute to neurodegeneration. For instance, the targeting of inflammatory pathways through agents like TNFSF8 could provide dual benefits of modulating immune responses while also addressing cognitive deficits[51].

Overall, while traditional pharmacotherapy for cognitive impairment often results in palliative effects, the integration of gene therapy and novel immunomodulatory strategies represents a transformative shift towards targeted and potentially curative treatments. Ongoing research and clinical trials will be essential to validate these approaches and assess their long-term efficacy and safety in the management of cognitive impairment.

6 Multidisciplinary Approaches to Treatment ​

6.1 Role of Healthcare Providers ​

Cognitive impairment presents a significant challenge across various patient populations, including those with HIV, multiple sclerosis (MS), and Parkinson's disease, necessitating a multidisciplinary approach to treatment. The complexity of cognitive disorders requires healthcare providers to adopt comprehensive strategies that integrate clinical, psychological, and social interventions.

In the context of HIV, cognitive impairment is increasingly recognized, particularly in individuals living with HIV (PLWH). Effective management involves a multifactorial approach that encompasses thorough assessment and patient-centered care. Key recommendations for healthcare providers include integrating medical history, physical examinations, brain imaging (especially MRI), neuropsychological testing, and lumbar puncture to identify underlying causes of cognitive decline. Given the ineffectiveness of pharmacological treatments for HIV-related cognitive decline, nonpharmacological interventions such as cognitive training and holistic rehabilitation programs are essential. Furthermore, routine screening and preventive care are crucial for early detection, while social and psychological support play critical roles in addressing the mental health issues exacerbated by cognitive decline in this population[53].

In the case of multiple sclerosis, cognitive impairment affects a substantial proportion of patients, impacting their quality of life. Healthcare providers are encouraged to optimize medical management of MS and co-morbidities, alongside implementing non-pharmacological strategies such as cognitive rehabilitation and exercise training. These strategies have shown promise in alleviating cognitive deficits, yet the current management of cognitive dysfunction in MS is often considered inadequate. Future directions should include defining optimal training intensities and integrating cognitive rehabilitation into clinical practice[10][54].

For Parkinson's disease, cognitive impairment is a challenging non-motor symptom that can occur at any stage of the disease. The absence of established pharmacological treatments necessitates a focus on cognition-based interventions. Healthcare providers should consider multimodal approaches that combine cognitive stimulation, cognitive training, and rehabilitation with adjunctive therapies such as exercise and non-invasive brain stimulation. Evidence suggests that such combinations may enhance various cognitive functions, including memory and executive functioning[11].

Overall, the role of healthcare providers in managing cognitive impairment involves the coordination of multidisciplinary teams that may include neuropsychologists, rehabilitation psychologists, and speech-language pathologists. Collaborative care models that integrate diverse expertise are vital for delivering comprehensive assessments and interventions tailored to individual patient needs. This holistic approach not only addresses cognitive deficits but also improves overall quality of life for affected individuals[55].

In conclusion, the treatment of cognitive impairment across different conditions emphasizes the importance of a multidisciplinary framework. Healthcare providers must prioritize comprehensive assessments, early detection, and the integration of both pharmacological and non-pharmacological interventions to effectively manage cognitive dysfunction and enhance patient outcomes.

6.2 Importance of Family Support ​

Cognitive impairment presents a significant challenge across various clinical contexts, necessitating a multidisciplinary approach to treatment that incorporates both medical and psychosocial strategies. The integration of family support into the treatment regimen is crucial for enhancing patient outcomes and managing caregiver burden.

Cognitive impairment can manifest in several conditions, including psychotic disorders, neurological diseases, and cancer treatments. Evidence-based clinical guidelines recommend that treatments such as cognitive remediation and cognitive compensation be offered to individuals experiencing cognitive deficits, particularly in psychosis-spectrum disorders. These treatments should be complemented by involving family members in the care process, as their understanding and support can significantly impact the recovery of their loved ones [56].

In the context of hematopoietic stem cell transplantation (HCT) and CAR-T cell therapy, cognitive impairment is a prevalent complication. Recommendations from expert consensus advocate for systematic cognitive assessments before and after therapy using validated instruments, such as the Montreal Cognitive Assessment (MoCA). If cognitive impairment is identified, a multidisciplinary approach is recommended, which may include reevaluating the therapeutic plan and considering referrals for rehabilitation [49].

Nonpharmacological interventions have also been shown to be effective in managing cognitive impairment. A systematic review indicated that physical-cognitive rehabilitation is the most effective nonpharmacological intervention for enhancing cognition in patients with unspecified cognitive impairment and dementia. Occupational therapy focused on dual-task interventions has been particularly beneficial for those with mild cognitive impairment [4]. These interventions emphasize the importance of combining cognitive and physical rehabilitation strategies to improve overall cognitive function.

For specific conditions such as schizophrenia, pharmacological treatments with second-generation antipsychotics are recommended, along with psychosocial interventions like cognitive remediation and physical exercise. These strategies aim to address cognitive deficits and enhance functional recovery [2].

In addition to formal treatments, the role of family support cannot be overstated. Families can provide essential emotional support and assist in cognitive rehabilitation efforts. Psychoeducation for caregivers is vital, as it equips them with the knowledge necessary to understand cognitive health needs and participate actively in the treatment process [56].

In summary, the treatment of cognitive impairment necessitates a comprehensive, multidisciplinary approach that integrates medical interventions, nonpharmacological strategies, and active family involvement. This holistic framework not only addresses the cognitive deficits experienced by patients but also supports the well-being of caregivers, ultimately leading to improved outcomes for both patients and their families.

7 Conclusion ​

The exploration of treatment options for cognitive impairment reveals a multifaceted landscape characterized by both pharmacological and non-pharmacological interventions. Key findings highlight the effectiveness of cholinesterase inhibitors and NMDA receptor antagonists in managing cognitive deficits across various neurodegenerative conditions, although the variability in individual responses necessitates personalized approaches. Non-pharmacological strategies, including cognitive training, physical exercise, and nutritional interventions, have demonstrated significant potential in enhancing cognitive function and improving quality of life. Furthermore, emerging therapies such as neurostimulation techniques, stem cell therapy, and gene therapy offer promising avenues for future research and clinical application. A multidisciplinary approach, involving healthcare providers and family support, is essential for optimizing treatment outcomes and addressing the complex needs of individuals experiencing cognitive impairment. Continued research is imperative to refine these interventions and establish effective protocols that cater to the diverse needs of affected populations, ultimately enhancing cognitive health and overall well-being.

References ​

  • [1] Steven M Greenberg. Vascular Contributions to Brain Health: Cross-Cutting Themes.. Stroke(IF=8.9). 2022. PMID:35000428. DOI: 10.1161/STROKEAHA.121.034921.
  • [2] Antonio Vita;Wolfgang Gaebel;Armida Mucci;Gabriele Sachs;Stefano Barlati;Giulia Maria Giordano;Gabriele Nibbio;Merete Nordentoft;Til Wykes;Silvana Galderisi. European Psychiatric Association guidance on treatment of cognitive impairment in schizophrenia.. European psychiatry : the journal of the Association of European Psychiatrists(IF=6.7). 2022. PMID:36059103. DOI: 10.1192/j.eurpsy.2022.2315.
  • [3] Elzbieta Miller;Agnieszka Morel;Justyna Redlicka;Igor Miller;Joanna Saluk. Pharmacological and Non-pharmacological Therapies of Cognitive Impairment in Multiple Sclerosis.. Current neuropharmacology(IF=5.3). 2018. PMID:29119933. DOI: 10.2174/1570159X15666171109132650.
  • [4] Luis Carlos Venegas-Sanabria;Iván Cavero-Redondo;Patricia Lorenzo-Garcia;Guillermo Sánchez-Vanegas;Celia Álvarez-Bueno. Efficacy of Nonpharmacological Interventions in Cognitive Impairment: Systematic Review And Network Meta-Analysis.. The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry(IF=3.8). 2024. PMID:39034265. DOI: 10.1016/j.jagp.2024.06.012.
  • [5] Paul S Farsai. Cognitive Impairment in Older Adults and Oral Health Considerations: Treatment and Management.. Clinics in geriatric medicine(IF=3.9). 2023. PMID:37045534. DOI: 10.1016/j.cger.2023.01.001.
  • [6] L S Schneider. New therapeutic approaches to Alzheimer's disease.. The Journal of clinical psychiatry(IF=4.6). 1996. PMID:9024334. DOI: .
  • [7] Jennifer G Goldman;Daniel Weintraub. Advances in the treatment of cognitive impairment in Parkinson's disease.. Movement disorders : official journal of the Movement Disorder Society(IF=7.6). 2015. PMID:26297863. DOI: 10.1002/mds.26352.
  • [8] Gretchen O Reynolds;Kim Willment;Seth A Gale. Mindfulness and Cognitive Training Interventions in Mild Cognitive Impairment: Impact on Cognition and Mood.. The American journal of medicine(IF=5.3). 2021. PMID:33385339. DOI: 10.1016/j.amjmed.2020.10.041.
  • [9] Eun Jin Kim;Yong-Chun Bahk;Hyeonju Oh;Won-Hye Lee;Jong-Sun Lee;Kee-Hong Choi. Current Status of Cognitive Remediation for Psychiatric Disorders: A Review.. Frontiers in psychiatry(IF=3.2). 2018. PMID:30337888. DOI: 10.3389/fpsyt.2018.00461.
  • [10] John DeLuca;Nancy D Chiaravalloti;Brian M Sandroff. Treatment and management of cognitive dysfunction in patients with multiple sclerosis.. Nature reviews. Neurology(IF=33.1). 2020. PMID:32372033. DOI: 10.1038/s41582-020-0355-1.
  • [11] Elisa Mantovani;Miriana Maria Bressan;Michele Tinazzi;Stefano Tamburin. Towards multimodal cognition-based treatment for cognitive impairment in Parkinson's disease: drugs, exercise, non-invasive brain stimulation and technologies.. Current opinion in neurology(IF=4.4). 2024. PMID:39132779. DOI: 10.1097/WCO.0000000000001310.
  • [12] Latha Velayudhan;Dominic Ffytche;Clive Ballard;Dag Aarsland. New Therapeutic Strategies for Lewy Body Dementias.. Current neurology and neuroscience reports(IF=5.2). 2017. PMID:28741230. DOI: 10.1007/s11910-017-0778-2.
  • [13] Francesco Patti. Treatment of cognitive impairment in patients with multiple sclerosis.. Expert opinion on investigational drugs(IF=4.1). 2012. PMID:22876911. DOI: 10.1517/13543784.2012.716036.
  • [14] Caroline Demily;Nicolas Franck. Cognitive remediation: a promising tool for the treatment of schizophrenia.. Expert review of neurotherapeutics(IF=3.4). 2008. PMID:18590474. DOI: 10.1586/14737175.8.7.1029.
  • [15] Zichen Zhang;Liuyi Chen;Yi Guo;Dan Li;Jingyu Zhang;Ling Liu;Wen Fan;Tao Guo;Siru Qin;Yadan Zhao;Zhifang Xu;Zelin Chen. The neuroprotective and neural circuit mechanisms of acupoint stimulation for cognitive impairment.. Chinese medicine(IF=5.7). 2023. PMID:36670425. DOI: 10.1186/s13020-023-00707-x.
  • [16] Ceri E Battle;Azmil H Abdul-Rahim;Susan D Shenkin;Jonathan Hewitt;Terry J Quinn. Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: a network meta-analysis.. The Cochrane database of systematic reviews(IF=9.4). 2021. PMID:33704781. DOI: 10.1002/14651858.CD013306.pub2.
  • [17] Pearl Behl;Jodi D Edwards;Alexander Kiss;Krista L Lanctot;David L Streiner;Sandra E Black;Donald T Stuss. Treatment effects in multiple cognitive domains in Alzheimer's disease: a two-year cohort study.. Alzheimer's research & therapy(IF=7.6). 2014. PMID:25484926. DOI: 10.1186/alzrt280.
  • [18] Jacqueline Birks;Leon Flicker. Investigational treatment for vascular cognitive impairment.. Expert opinion on investigational drugs(IF=4.1). 2007. PMID:17461738. DOI: 10.1517/13543784.16.5.647.
  • [19] Iracema Leroi;Deborah Collins;Laura Marsh. Non-dopaminergic treatment of cognitive impairment and dementia in Parkinson's disease: a review.. Journal of the neurological sciences(IF=3.2). 2006. PMID:16806271. DOI: 10.1016/j.jns.2006.05.021.
  • [20] Ying Li;Shan Hai;Yan Zhou;Bi Rong Dong. Cholinesterase inhibitors for rarer dementias associated with neurological conditions.. The Cochrane database of systematic reviews(IF=9.4). 2015. PMID:25734590. DOI: 10.1002/14651858.CD009444.pub3.
  • [21] L S Schneider. New therapeutic approaches to cognitive impairment.. The Journal of clinical psychiatry(IF=4.6). 1998. PMID:9731544. DOI: .
  • [22] Tom C Russ;Joanne R Morling. Cholinesterase inhibitors for mild cognitive impairment.. The Cochrane database of systematic reviews(IF=9.4). 2012. PMID:22972133. DOI: 10.1002/14651858.CD009132.pub2.
  • [23] Rahim Badrfam;Atefeh Zandifar. NMDA receptor-modulating treatments for cognitive deficits in patients with bipolar disorder: A narrative review.. General hospital psychiatry(IF=3.7). 2025. PMID:40886395. DOI: 10.1016/j.genhosppsych.2025.08.013.
  • [24] Ting Zhang;Chang Liu;Ning Zhong;Yichen Wang;Yiyun Huang;Xiaoqin Zhang. Advances in the Treatment of Cognitive Impairment in Schizophrenia: Targeting NMDA Receptor Pathways.. International journal of molecular sciences(IF=4.9). 2024. PMID:39408997. DOI: 10.3390/ijms251910668.
  • [25] Joanna C Neill;Samuel Barnes;Samantha Cook;Ben Grayson;Nagi F Idris;Samantha L McLean;Shikha Snigdha;Lakshmi Rajagopal;Michael K Harte. Animal models of cognitive dysfunction and negative symptoms of schizophrenia: focus on NMDA receptor antagonism.. Pharmacology & therapeutics(IF=12.5). 2010. PMID:20705091. DOI: 10.1016/j.pharmthera.2010.07.004.
  • [26] C G Parsons;W Danysz;G Quack. Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist--a review of preclinical data.. Neuropharmacology(IF=4.6). 1999. PMID:10465680. DOI: 10.1016/s0028-3908(99)00019-2.
  • [27] J Kornhuber;M Weller. Psychotogenicity and N-methyl-D-aspartate receptor antagonism: implications for neuroprotective pharmacotherapy.. Biological psychiatry(IF=9.0). 1997. PMID:9018383. DOI: 10.1016/S0006-3223(96)00047-9.
  • [28] Neelam Thakurathi;Brenda Vincenzi;David C Henderson. Assessing the prospect of donepezil in improving cognitive impairment in patients with schizophrenia.. Expert opinion on investigational drugs(IF=4.1). 2013. PMID:23215841. DOI: 10.1517/13543784.2013.750650.
  • [29] Jos Prickaerts;Jill Kerckhoffs;Nina Possemis;Wendy van Overveld;Frank Verbeek;Teun Grooters;Anke Sambeth;Arjan Blokland. Roflumilast and cognition enhancement: A translational perspective.. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie(IF=7.5). 2024. PMID:39591666. DOI: 10.1016/j.biopha.2024.117707.
  • [30] Philipp Karschnia;Michael W Parsons;Jorg Dietrich. Pharmacologic management of cognitive impairment induced by cancer therapy.. The Lancet. Oncology(IF=35.9). 2019. PMID:30723041. DOI: 10.1016/S1470-2045(18)30938-0.
  • [31] Wen-Yu Hsu;Hsien-Yuan Lane;Chieh-Hsin Lin. Medications Used for Cognitive Enhancement in Patients With Schizophrenia, Bipolar Disorder, Alzheimer's Disease, and Parkinson's Disease.. Frontiers in psychiatry(IF=3.2). 2018. PMID:29670547. DOI: 10.3389/fpsyt.2018.00091.
  • [32] Klaus Steinbrück;Reinaldo Fernandes;Giuliano Bento;Rafael Vasconcelos;Gustavo Stoduto;Thomas Auel;Lúcio F Pacheco-Moreira. Inferior Right Hepatic Vein: A Useful Anatomic Variation for Isolated Resection of Segment VIII.. Case reports in surgery(IF=0.5). 2013. PMID:24024060. DOI: 10.1155/2013/371264.
  • [33] Juleen Rodakowski;Ester Saghafi;Meryl A Butters;Elizabeth R Skidmore. Non-pharmacological interventions for adults with mild cognitive impairment and early stage dementia: An updated scoping review.. Molecular aspects of medicine(IF=10.3). 2015. PMID:26070444. DOI: .
  • [34] Clive Ballard;Zunera Khan;Hannah Clack;Anne Corbett. Nonpharmacological treatment of Alzheimer disease.. Canadian journal of psychiatry. Revue canadienne de psychiatrie(IF=3.8). 2011. PMID:22014691. DOI: 10.1177/070674371105601004.
  • [35] Alex Bahar-Fuchs;Linda Clare;Bob Woods. Cognitive training and cognitive rehabilitation for persons with mild to moderate dementia of the Alzheimer's or vascular type: a review.. Alzheimer's research & therapy(IF=7.6). 2013. PMID:23924584. DOI: 10.1186/alzrt189.
  • [36] Yuan-Yuan Wang;Xiao-Xian Wang;Lei Chen;Yan Liu;Ya-Ru Li. A systematic review and network meta-analysis comparing various non-pharmacological treatments for older people with mild cognitive impairment.. Asian journal of psychiatry(IF=4.5). 2023. PMID:37270875. DOI: 10.1016/j.ajp.2023.103635.
  • [37] Jason W Krellman;Giulia Mercuri. Cognitive Interventions for Neurodegenerative Disease.. Current neurology and neuroscience reports(IF=5.2). 2023. PMID:37428401. DOI: 10.1007/s11910-023-01283-1.
  • [38] C Groot;A M Hooghiemstra;P G H M Raijmakers;B N M van Berckel;P Scheltens;E J A Scherder;W M van der Flier;R Ossenkoppele. The effect of physical activity on cognitive function in patients with dementia: A meta-analysis of randomized control trials.. Ageing research reviews(IF=12.4). 2016. PMID:26607411. DOI: .
  • [39] Giacomo Farì;Paola Lunetti;Giovanni Pignatelli;Maria Vittoria Raele;Alessandra Cera;Giulia Mintrone;Maurizio Ranieri;Marisa Megna;Loredana Capobianco. The Effect of Physical Exercise on Cognitive Impairment in Neurodegenerative Disease: From Pathophysiology to Clinical and Rehabilitative Aspects.. International journal of molecular sciences(IF=4.9). 2021. PMID:34769062. DOI: 10.3390/ijms222111632.
  • [40] Junjie Peng;Renjie Chang;Xinghong Wei;Zhimin Yin;Qin Liu. Effect of non-pharmacological interventions in people with cognitive frailty: a systematic review and network meta-analysis.. BMC public health(IF=3.6). 2024. PMID:39354435. DOI: 10.1186/s12889-024-20079-7.
  • [41] Mónika Fekete;Andrea Lehoczki;Stefano Tarantini;Vince Fazekas-Pongor;Tamás Csípő;Zoltán Csizmadia;János Tamás Varga. Improving Cognitive Function with Nutritional Supplements in Aging: A Comprehensive Narrative Review of Clinical Studies Investigating the Effects of Vitamins, Minerals, Antioxidants, and Other Dietary Supplements.. Nutrients(IF=5.0). 2023. PMID:38140375. DOI: 10.3390/nu15245116.
  • [42] Blanka Klímová;Martin Vališ. Nutritional Interventions as Beneficial Strategies to Delay Cognitive Decline in Healthy Older Individuals.. Nutrients(IF=5.0). 2018. PMID:30011956. DOI: 10.3390/nu10070905.
  • [43] George S Vlachos;Nikolaos Scarmeas. Dietary interventions in mild cognitive impairment and dementia.. Dialogues in clinical neuroscience(IF=8.9). 2019. PMID:31607782. DOI: .
  • [44] Laia Gutierrez;Alexandre Folch;Melina Rojas;José Luis Cantero;Mercedes Atienza;Jaume Folch;Antoni Camins;Agustín Ruiz;Christopher Papandreou;Mònica Bulló. Effects of Nutrition on Cognitive Function in Adults with or without Cognitive Impairment: A Systematic Review of Randomized Controlled Clinical Trials.. Nutrients(IF=5.0). 2021. PMID:34835984. DOI: 10.3390/nu13113728.
  • [45] Qi Zhang;Peng-Peng Zhu;Lun Yang;Ai-Song Guo. Research hotspots and trends in transcranial magnetic stimulation for cognitive impairment: A bibliometric analysis from 2014 to 2023.. World journal of psychiatry(IF=3.4). 2024. PMID:39474374. DOI: 10.5498/wjp.v14.i10.1592.
  • [46] Asli Demirtas-Tatlidede;Andrew M Vahabzadeh-Hagh;Alvaro Pascual-Leone. Can noninvasive brain stimulation enhance cognition in neuropsychiatric disorders?. Neuropharmacology(IF=4.6). 2013. PMID:22749945. DOI: .
  • [47] Clara Sanches;Chloé Stengel;Juliette Godard;Justine Mertz;Marc Teichmann;Raffaella Migliaccio;Antoni Valero-Cabré. Past, Present, and Future of Non-invasive Brain Stimulation Approaches to Treat Cognitive Impairment in Neurodegenerative Diseases: Time for a Comprehensive Critical Review.. Frontiers in aging neuroscience(IF=4.5). 2020. PMID:33551785. DOI: 10.3389/fnagi.2020.578339.
  • [48] X Lv;H Niu. Mesenchymal Stem Cell Transplantation for the Treatment of Cognitive Frailty.. The journal of nutrition, health & aging(IF=4.0). 2021. PMID:34179936. DOI: 10.1007/s12603-021-1632-4.
  • [49] Vanessa E Kennedy;Nausheen Ahmed;Andy Artz;Neel S Bhatt;Rachel Custatis;Manuel R Espinoza-Gutarra;Shatha Farhan;Robert J Ferguson;Betty Hamilton;Hannah Katz;Debra L Kelly;Jennifer M Knight;Catherine Lee;Adam Lin;Richard Lin;Lathika Mohanraj;Pashna Munshi;Mariam Nawas;Ashley M Nelson;Silvina Odstracil;Rebecca Olin;Rachel Phelan;Kelly E Rentscher;Hélène Schoemans;Anthony Sung;Mallory R Taylor;Wiliam Wood;Carrie H Yuen;Reena V Jayani-Kosarzycki. Assessing cognitive function in transplantation and chimeric antigen receptor t cell therapy recipients: Expert recommendations from the survivorship, aging and biobehavioral special interest groups of the American Society for Transplantation and Cellular Therapy.. Transplantation and cellular therapy(IF=4.4). 2025. PMID:40614969. DOI: 10.1016/j.jtct.2025.06.026.
  • [50] Janice R Naegele;Xu Maisano;Jia Yang;Sara Royston;Efrain Ribeiro. Recent advancements in stem cell and gene therapies for neurological disorders and intractable epilepsy.. Neuropharmacology(IF=4.6). 2010. PMID:20146928. DOI: 10.1016/j.neuropharm.2010.01.019.
  • [51] Xixi Wu;Qingyan Yang;Yudi Xie;Lingfeng Xia;Jiatao Li;Wenting An;Xiao Lu. Drug-targeted Mendelian randomization analysis combined with transcriptome sequencing to explore the molecular mechanisms associated with cognitive impairment.. Journal of Alzheimer's disease : JAD(IF=3.1). 2025. PMID:40267292. DOI: 10.1177/13872877251335891.
  • [52] Shalini Mani;Divya Jindal;Manisha Singh. Gene Therapy, A Potential Therapeutic Tool for Neurological and Neuropsychiatric Disorders: Applications, Challenges and Future Perspective.. Current gene therapy(IF=3.3). 2023. PMID:35345999. DOI: 10.2174/1566523222666220328142427.
  • [53] Kate Alford;Clara O'Brien;Sube Banerjee;Colin Fitzpatrick;Jaime H Vera. Managing cognitive impairment in people with HIV.. Current opinion in infectious diseases(IF=4.0). 2025. PMID:39602088. DOI: 10.1097/QCO.0000000000001078.
  • [54] Ermelinda De Meo;Emilio Portaccio;Raffaello Bonacchi;Jasmine Giovannoli;Claudia Niccolai;Maria Pia Amato. An update on the treatment and management of cognitive dysfunction in patients with multiple sclerosis.. Expert review of neurotherapeutics(IF=3.4). 2025. PMID:39801437. DOI: 10.1080/14737175.2025.2450788.
  • [55] Katlin R Schultz;Shana McGrath;Therese Anne Keary;Chelsea K Meng;Elisabeth Batchos;Lauren Evans;Danelle Fields;Annie Cummings;Nicole Fornalski. A multidisciplinary approach to assessment and management of long COVID cognitive concerns.. Life sciences(IF=5.1). 2024. PMID:39299386. DOI: 10.1016/j.lfs.2024.123068.
  • [56] Shayden Bryce;Amanda Sorenson;Debbie Warner;Alex Stainton;Alice Medalia;Caroline Cellard;Isabel Zbukvic;Jacquie Uren;Jessy Smith;Lauren Libeson;Wilma Peters;Kelly Allott. How Can We Better Assist Caregivers With Understanding and Addressing the Cognitive Health Needs of People With Psychotic Disorders?. Schizophrenia bulletin(IF=4.8). 2025. PMID:40401786. DOI: 10.1093/schbul/sbaf062.

MaltSci Intelligent Research Services ​

Search for more papers on MaltSci.com ​

Cognitive Impairment · Pharmacological Treatments · Non-Pharmacological Interventions · Personalized Treatment · Emerging Therapies

© 2025 MaltSci